Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Harvard Business School
McKinsey
Baxter

Last Updated: January 16, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for AKB-6548


Email this page to a colleague

« Back to Dashboard

What is the drug development status for AKB-6548?

AKB-6548 is an investigational drug.

There have been 38 clinical trials for AKB-6548. The most recent clinical trial was a Phase 3 trial, which was initiated on February 1st 2016.

The most common disease conditions in clinical trials are Renal Insufficiency, Chronic, Kidney Diseases, and Anemia. The leading clinical trial sponsors are Akebia Therapeutics, Aerpio Therapeutics, and Mitsubishi Tanabe Pharma Corporation.

There are twenty-two US patents protecting this investigational drug and two hundred and eight international patents.

Recent Clinical Trials for AKB-6548
TitleSponsorPhase
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney DiseaseAkebia TherapeuticsPhase 3
Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating AgentsAkebia TherapeuticsPhase 3
Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)Akebia Therapeutics Inc.Phase 2

See all AKB-6548 clinical trials

Clinical Trial Summary for AKB-6548

Top disease conditions for AKB-6548
Top clinical trial sponsors for AKB-6548

See all AKB-6548 clinical trials

US Patents for AKB-6548

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AKB-6548 ⤷  Sign up for a Free Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Sign up for a Free Trial
AKB-6548 ⤷  Sign up for a Free Trial Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof Akebia Therapeutics, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
AKB-6548 ⤷  Sign up for a Free Trial Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY) ⤷  Sign up for a Free Trial
AKB-6548 ⤷  Sign up for a Free Trial Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides Akebia Therapeutics, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
AKB-6548 ⤷  Sign up for a Free Trial Oral drug dosage forms having desired drug release profiles and uses thereof Triastek, Inc. (Nanjing, CN) ⤷  Sign up for a Free Trial
AKB-6548 ⤷  Sign up for a Free Trial Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators Pfizer Inc. (New York, NY) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AKB-6548

Drugname Country Document Number Estimated Expiration Related US Patent
AKB-6548 Australia AU2017261372 2036-05-05 ⤷  Sign up for a Free Trial
AKB-6548 Canada CA3023278 2036-05-05 ⤷  Sign up for a Free Trial
AKB-6548 China CN107847398 2036-05-05 ⤷  Sign up for a Free Trial
AKB-6548 European Patent Office EP3452003 2036-05-05 ⤷  Sign up for a Free Trial
AKB-6548 Hong Kong HK1249728 2036-05-05 ⤷  Sign up for a Free Trial
AKB-6548 Japan JP2019520866 2036-05-05 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Moodys
Harvard Business School
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.